Ramixsole 1 mg 30 tablets

Trade name:

Ramixole

Ramixole

Properties

Antiparkinsonian drug, dopamine receptor agonist. It is believed that the mechanism of action is associated with the ability of pramipexole to stimulate dopamine receptors in the striatum. This is confirmed by the effect on the level of impulsation in striatal neurons due to the activation of dopamine receptors in the striatum and substantia nigra.

It cannot be ruled out that pramipexole inhibits prolactin secretion in humans.

Indications

Treatment of Parkinson’s disease (in the form of monotherapy and in combination with levodopa).

Dosage and administration

The optimal dosage regimen is determined by the doctor. Compliance of the used dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

For adults, when taken orally, the initial dose is 375 mcg / day in 3 divided doses. The dose should be increased every 5-7 days until the maximum therapeutic effect is achieved, which is observed when taking 1.5-4.5 mg / day.

It is recommended to stop treatment within 1 week.

Contraindications

Hypersensitivity to pramipexole.

Breast-feeding.

Precautionary measures:

Side effects

From the side of the central nervous system and peripheral nervous system: drowsiness, dyskinesia, hallucinations; in some cases — insomnia. With a rapid decrease in the dose of pramipexole, as well as with abrupt cancellation, the development of NMS is possible.

From the digestive system: nausea, constipation.

Since the cardiovascular system: in some cases, at the beginning of treatment — arterial hypotension (especially with a gradual increase in dose for too short a time).